Grifols, S.A.

NASDAQ:GRFS

Drug Manufacturers - General

Healthcare
$8.47 +0.34%

+$0.03 today

Market cap
$7.17B
Beta
1.17
P/E (TTM)
14.7
EPS (TTM)
$0.61
Dividend yield
1.67%
52W Low $7.26High $11.14

Volume 0.59M

Average 0.69M

GRFS EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Grifols, S.A.NASDAQ: GRFS

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA growth accelerates

Q2 FY2026 EBITDA of €535M rose 21.9% year over year, ahead of the +6.1% change in trailing-twelve-month EBITDA. Sequentially, it rose 48.3% from the prior quarter. Over 3 fiscal years it compounded at +10.8% a year.

Context

  • EBITDA amounted to 22.5% of revenue in FY2025, up 1.9 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of €1.8B (+11.2%) for the fiscal year ending Dec 2026, a step up from the +9.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
€535M+48.3% QoQ
Last fiscal yearDec 2025
€1.62B+9.4% YoY
LTMJun 2026
€1.75B+6.1% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+21.9%-21.0%-42.9 pp
1 year+9.4%+11.2%+1.8 pp
3-year CAGR+10.8%+11.4%+0.6 pp
5-year CAGR+9.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

EUR · from the income statement

Latest · FY2025
1.62B EUR
Year-over-year change
+9.4%
4-year CAGR
+14.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How GRFS compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +6.1% is the 4th highest of 9, against a peer median of -9.8%.
  • EBITDA amounts to 23.5% of revenue for GRFS, versus a peer median of 22.0%.
GRFS Competitors
EBITDA for GRFS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABTAbbott LaboratoriesLTM Sep 2026$9.71B USD-17.7%+0.1%20.1%
BDXBecton, Dickinson and CompanyLTM Sep 2026$4.74B USD-1.9%+1.5%23.4%
GRFSGrifols, S.A.LTM Jun 2026€1.75B EUR+6.1%+10.8%23.5%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$514.7M USD-22.7%—19.9%
TECHBio-Techne CorporationLTM Sep 2026$328.77M USD+48.3%-9.1%26.8%
HAEHaemonetics CorporationLTM Jun 2026$261.21M USD-30.7%+1.0%19.3%
ADMAADMA Biologics, Inc.LTM Jun 2026$232.99M USD+42.8%—45.5%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026-$55.57M USD+77.9%—26.6%
QDELQuidelOrtho CorporationLTM Mar 2026-$548.8M USD-290.2%—20.7%
Peer median (excluding GRFS) —-9.8%+0.6%22.0%

Competitors are the stored peer set for GRFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.93B6.06B6.59B7.21B7.23B
Cost of Revenue2.97B3.85B4.11B4.42B4.65B
Gross Profit1.96B2.21B2.48B2.79B2.58B
Gross Margin39.8%36.5%37.7%38.7%35.7%
Research & Development354.88M361.14M395.28M384.04M358.28M
Selling, General & Admin1.06B1.11B1.27B1.14B1.02B
Operating Expenses1.37B1.43B1.7B1.6B1.39B
Depreciation & Amortization359.77M410.98M446.42M437.9M432.24M
EBITDA944.03M1.19B1.17B1.48B1.62B
EBITDA Margin19.1%19.7%17.7%20.6%22.5%
Operating Income595.06M782.44M782.32M1.19B1.19B
Operating Margin12.1%12.9%11.9%16.5%16.4%
Interest Income11.55M33.86M62.43M48.05M32.66M
Interest Expense233.81M444.54M516.06M773.16M600.33M
Other Income / Expenses(244.61M)(444.42M)(575.3M)(748.02M)(596.49M)
Income Before Tax350.45M338.01M207.02M444M590.73M
Pre-Tax Margin7.1%5.6%3.1%6.2%8.2%
Income Tax Expense85.13M90.11M43.35M231.19M110.46M
Net Income188.73M185.04M42.32M156.92M386.13M
Net Margin3.8%3.1%0.6%2.2%5.3%
EPS (Basic)0.270.310.090.230.57
EPS (Diluted)0.270.310.090.230.57
Weighted Avg Shares681.56M679.81M679.76M680.02M680.58M
Weighted Avg Shares (Diluted)681.56M679.81M679.76M680.02M680.58M

Grifols, S.A.

NASDAQ:GRFS

Intrinsic Alpha fair value

Locked

Current Price

$8.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.